What is it about?
Chronic Lymphocytic Leukemia type B (CLL-B), which did not meet the standard treatment criteria for malignant hematological diseases due to mutations in the P-53 gene, with progression to Richter Syndrome.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
In the context of a heterogeneous condition such as CLL-B, this cheap and safe method, ELISA seems to provide a useful prognostic tool capable of identifying patients who can be considered candidates for therapeutic, targeted, personalized strategies.
Perspectives
-P-53 Gene mutations are the most common genetic abnormalities of cancer. They have been extensively studied in various mature B cell malignancies, including Chronic Lymphocytic Leukemia, (CLL). - In recent years, more attention has been paid to the importance of the p53 expressed protein in CLL, and a combination with low survival and non-response to classical conventional chemotherapy, due to mutations in the P-53 gene, with progression to Richter Syndrome. -Identifying different P-53 gene mutations is very important because these mutations have an impact on patients' clinical course in CLL with the p-53 protein mutant isoform.
Professor Aurelian Udristioiu
Hematology and Oncology Specialists LLC
Read the Original
This page is a summary of: The Role p-53 Protein in Oncogenesis of Non-hodgkin Malignant Lymphomas, November 2022, Sciencedomain International,
DOI: 10.9734/bpi/cimms/v6/3624b.
You can read the full text:
Resources
Contributors
The following have contributed to this page
